|1.||Zhong, Z John: 14 articles (05/2014 - 09/2009)|
|2.||Freimuth, William W: 10 articles (05/2014 - 09/2009)|
|3.||Petri, Michelle A: 9 articles (05/2014 - 09/2009)|
|4.||Stohl, William: 9 articles (02/2014 - 01/2008)|
|5.||Merrill, Joan T: 8 articles (02/2014 - 01/2008)|
|6.||Wallace, Daniel J: 7 articles (12/2015 - 09/2009)|
|7.||Ginzler, Ellen M: 7 articles (02/2014 - 01/2008)|
|8.||D'Cruz, David P: 6 articles (08/2015 - 07/2012)|
|9.||Chatham, W Winn: 6 articles (02/2014 - 09/2009)|
|10.||Freimuth, William: 6 articles (11/2012 - 01/2008)|
|1.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
08/01/2014 - "The published clinical trials data showed that in patients with active systemic lupus erythematosus (SLE), belimumab effectively reduced peripheral B-cell levels and improved disease activity. "
12/01/2015 - "Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices."
09/15/2009 - "To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). "
01/01/2015 - "BAFF neutralization with the fully humanized monoclonal antibody belimumab has already shown success in human systemic lupus erythematosus and, along with another anti-BAFF reagent blisibimod, is currently undergoing Phase II and III clinical trials in AAV. "
02/01/2014 - "Belimumab in systemic lupus erythematosus -- what can be learned from longterm observational studies?"
04/01/2015 - "Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis."
04/01/2013 - "Further studies are needed to determine the efficacy of belimumab for patients with severe lupus nephritis and with active involvement of the central nervous system. "
02/01/2015 - "Studies of belimumab in lupus nephritis are ongoing that may clarify the role of this agent in the clinical management of SLE. "
04/01/2015 - "In addition, the extensive pharmacokinetics and clinical implications are exemplified in this review with belimumab's comparison with standard therapeutic guidelines for the treatment of lupus nephritis. "
04/01/2015 - "This article explains the precise mechanism of action of belimumab on the soluble protein BlyS that plays a major role in the pathogenesis of lupus nephritis. "
05/01/2014 - "In pooled analysis, significantly greater improvements in PCS, SF-36 vitality domain, and FACIT-Fatigue scores at week 52 were evident with both belimumab doses. "
09/01/2015 - "Response to: 'belimumab and the measurement of fatigue' by Mazzoni."
09/01/2015 - "Belimumab and the measurement of fatigue."
01/01/2015 - "The anti-Blys/BAFF antibody belimumab showed prevention of SLE flares, glucocorticoid sparing, and significant improvement in the quality of life of SLE patients, in part by drastically reducing immune complex mediated fatigue. "
12/01/2013 - "Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. "
01/01/2013 - "Over 52 weeks, rates of renal flare, renal remission, renal organ disease improvement (assessed by Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index and British Isles Lupus Assessment Group), proteinuria reduction, grade 3/4 proteinuria, and serologic activity favored belimumab, although the between-group differences in most renal outcomes were not significant. "
07/01/2012 - "Belimumab-treated patients experienced significant sustained reductions in IgG and autoantibodies and improvement in C3/C4 levels, resulting in greater positive-to-negative conversion rates for IgG anti-double-stranded DNA (anti-dsDNA), anti-Sm, anticardiolipin, and anti-ribosomal P autoantibodies and normalization of hypergammaglobulinemia and low C3/C4 levels. "
|3.||hLL2 agent (epratuzumab)
|4.||DNA (Deoxyribonucleic Acid)
|6.||Immunoglobulin G (IgG)
|7.||Antigen-Antibody Complex (Immune Complex)
|9.||B-Cell Activating Factor